Search

Vir Biotechnology Inc

Chiusa

SettoreSettore sanitario

11.7 5.31

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

10.89

Massimo

11.94

Metriche Chiave

By Trading Economics

Entrata

206M

80M

Vendite

239M

239M

EPS

0.47

Margine di Profitto

33.514

Dipendenti

367

EBITDA

201M

78M

Raccomandazioni

By TipRanks

Raccomandazioni

Fortemente da comprare

Previsioni per 12 mesi

+91.42% upside

Dividendi

By Acuity

Utili prossimi

4 nov 2026

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

492M

2B

Apertura precedente

6.39

Chiusura precedente

11.7

Vir Biotechnology Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

9 ott 2026, 20:02 UTC

Correlated Moves
Event
Social Media

Vir Biotechnology receives FDA Fast Track designation for VIR-5500, a PSMA-targeted treatment for metastatic castration-resistant prostate cancer.

8 ott 2026, 21:01 UTC

Event

Vir Biotechnology receives FDA Fast Track designation for its investigational treatment VIR-5500 for late-line metastatic castration-resistant prostate cancer.

7 ott 2026, 20:07 UTC

News
Social Media

Vir Biotechnology's shares fell following the announcement of David Liu as Chief Medical Officer, despite HC Wainwright reaffirming a Buy rating with a $22 price target.

6 ott 2026, 20:40 UTC

Vir Biotechnology Inc has advanced in after-market trading, rebounding from earlier lows and achieving its highest cumulative return since Tuesday's close.

5 ott 2026, 20:01 UTC

Vir Biotechnology Inc is trading sharply higher, reaching a cumulative return of nearly 6%, near the upper end of its one-month trading range.

2 ott 2026, 20:07 UTC

Vir Biotechnology Inc shares fell sharply, continuing a decline from Thursday's close, despite rebounding earlier in the session.

1 ott 2026, 20:13 UTC

Vir Biotechnology Inc is advancing in after-market trading, holding steady above its 20-day moving average with a cumulative return since Thursday's close.

30 set 2026, 22:56 UTC

Vir Biotechnology Inc traded modestly lower in after-market hours, continuing a downward trend since Wednesday's close, despite remaining above its 20-day moving average.

29 set 2026, 20:02 UTC

News

Vir Biotechnology is advancing after partnering with Astellas, securing $335 million to enhance its PRO-XTEN platform and support its Phase 3 hepatitis delta program.

25 set 2026, 19:55 UTC

Vir Biotechnology Inc shares fell, continuing a decline over the past three sessions, and remain below Thursday's close and the 20-day moving average.

24 set 2026, 20:07 UTC

Vir Biotechnology Inc's shares are declining, continuing a downward trend since Wednesday, amid notable selling pressure and unfavorable broader market conditions.

23 set 2026, 20:31 UTC

Vir Biotechnology Inc experienced a notable decline in after-market trading, reaching a low and positioned around the middle of its one-month trading range.

22 set 2026, 23:31 UTC

Vir Biotechnology Inc has seen a significant decline during after-market trading, with volatility indicating a sharp downturn since Tuesday's close.

21 set 2026, 20:31 UTC

Vir Biotechnology Inc has advanced in after-market trading, reaching its highest cumulative return since Monday's close and positioned above its 20-day moving average.

18 set 2026, 19:55 UTC

Vir Biotechnology Inc shares fell sharply, reaching their lowest point around midday and remaining notably below the 20-day moving average.

17 set 2026, 20:07 UTC

Correlated Moves

Vir Biotechnology is higher amid a biotech sector rally, supported by the SPDR S&P Biotech ETF's rise following Moderna's positive cancer vaccine results.

16 set 2026, 23:06 UTC

Vir Biotechnology Inc is trading modestly higher during after-market hours, continuing a routine pattern with limited fluctuations since Wednesday's close.

15 set 2026, 23:41 UTC

Vir Biotechnology Inc shares are lower in after-market hours, following a broader market decline linked to a drop in the New York Empire State Manufacturing Index.

14 set 2026, 20:13 UTC

Vir Biotechnology Inc shares are higher in after-market hours, continuing a trend of three consecutive sessions in the same direction. No specific news was identified.

11 set 2026, 20:08 UTC

Vir Biotechnology Inc shares are higher during Friday's session, reflecting broader market trends. The stock experienced volatility, reaching a high shortly after the open.

9 set 2026, 20:07 UTC

Vir Biotechnology Inc shares are lower today, breaking a trend of higher daily closes. No specific news was identified to explain the decline.

3 set 2026, 19:46 UTC

Vir Biotechnology Inc shares are lower during Thursday's session, reversing early gains amid significant volatility. No specific news was identified to explain the decline.

2 set 2026, 23:16 UTC

Vir Biotechnology shares are lower in after-market trading, despite strong one-month performance. The stock remains above its 20-day moving average.

1 set 2026, 22:06 UTC

Social Media

Vir Biotechnology Inc. has a market cap of $1.6 billion and cash of $1 billion. Shares are higher in after-market trading following recent strong performance.

28 ago 2026, 20:08 UTC

Vir Biotechnology Inc shares are lower today, continuing a decline since Thursday amid rising U.S. Treasury yields and broader market pressures.

27 ago 2026, 20:08 UTC

Vir Biotechnology Inc shares are higher, reflecting a steady upward trend since Wednesday. Broader market conditions may be contributing to this positive movement.

26 ago 2026, 20:08 UTC

Vir Biotechnology Inc is higher in Wednesday's session, continuing its upward trend since Tuesday's close, despite earlier fluctuations in price.

25 ago 2026, 20:09 UTC

Social Media

Vir Biotechnology is gaining as social media discussions highlight its $1 billion cash position and potential catalysts, despite earlier session pullbacks.

24 ago 2026, 21:01 UTC

Vir Biotechnology Inc. shares are trading higher in after-market hours, continuing a recent upward trend amid a rebound in the bond market and lower Treasury yields.

21 ago 2026, 20:02 UTC

Correlated Moves

Vir Biotechnology Inc. shows upward momentum, reflecting significant gains since Thursday's close, amid positive trends in the healthcare sector and broader biotechnology market.

Confronto tra pari

Modifica del prezzo

Vir Biotechnology Inc Previsione

Obiettivo di Prezzo

By TipRanks

91.42% in crescita

Previsioni per 12 mesi

Media 21.286 USD  91.42%

Alto 30 USD

Basso 15 USD

Basato su 8 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Vir Biotechnology Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

8 ratings

8

Acquista

0

Mantieni

0

Vendi

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Vir Biotechnology Inc

Vir Biotechnology, Inc., an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company's preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV). The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune, LLC; collaboration with WuXi Biologics (Hong Kong) Limited and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A, as well as license agreement with Sanofi for three clinical-stage masked T-cell engagers (TCEs) and exclusive use of the protease-cleavable masking platform for oncology and infectious diseases. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. The company was incorporated in 2016 and is headquartered in San Francisco, California.